Despite the involvement of primary immune factors in the pathogenesis of sIBM, this disease remains resistant to most immunotherapies. In this respect, sIBM resembles primary progressive multiple ...

US biotech Abcuro has reeled in $200 million in third-round financing that should allow it to complete its pivotal trial of lead drug ulviprubart and file it for approval for inclusion body ...